ArticleJournal of biochemical and molecular toxicology2026
Evaluation of Anti-Tumorigenic Effects of Curcumin and Baicalein in 7,12-Dimethylbenz[a] Anthracene-Induced Mammary Gland Tumorigenesis in Wistar Rats.
Article in Journal of biochemical and molecular toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mammary tumor is one of the most common neoplasms in females and remains a major therapeutic challenge due to the high cost and adverse effects of conventional chemotherapy. Therefore, herbal products such as curcumin, baicalein and their combination are used which have anti-inflammatory effects and various other pharmacological effects. The present study evaluated the effects of curcumin and baicalein against mammary tumor induced by 7,12-dimethylbenz[a]anthracene (DMBA) in Wistar rats. Thirty-eight virgin female rats were divided into five groups: Group I (SHAM), Group II (DMBA @ 80 mg/kg BW orally single dose), Group III (DMBA @ 80 mg/kg BW orally + curcumin @ 100 mg/kg BW orally), Group IV (DMBA @ 80 mg/kg BW orally + baicalein @10 mg/kg BW i.p.), and Group V (DMBA @80 mg/kg + curcumin @100 mg/kg BW + baicalein @10 mg/kg BW). Curcumin and baicalein treatment demonstrated significant efficacy. Only small palpable growths were observed in treated groups and mild early neoplastic alterations were detected histologically, with the lowest incidence in the combination group. Curcumin and baicalein supplementation significantly ameliorated the DMBA induced changes in the body weight, hematological parameters (Hb, PCV, TEC, TLC, DLC), biochemical parameters (AST, ALT, ALKP, Total protein, glucose, BUN, Creatinine), oxidative stress parameters (NO, LPO, SOD, and Catalase), and pro-inflammatory cytokines (IL-I, IL-6, TNF-α). Moreover, immunohistochemistry and RT-PCR of epithelial-mesenchymal transition markers (e-cadherin, vimentin, α-smooth muscle actin) confirmed the ameliorative effect of curcumin and baicalein, most pronounced in the combination group. These findings suggest that curcumin and baicalein may exert synergistic beneficial effects, supporting their potential as chemopreventive agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.